Miao Duan
Overview
Explore the profile of Miao Duan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Y, Chen L, Duan M
Front Pediatr
. 2025 Feb;
13:1392927.
PMID: 39963347
Glutaric acidemia type II (GAII) is an autosomal recessive genetic metabolic disorder associated with mitochondrial dysfunction, characterized by multiple acyl-CoA dehydrogenase deficiency that affects fatty acid metabolism. Necrotizing enterocolitis (NEC)...
2.
Duan M, Kong Q, Wang H, Li Y
Helicobacter
. 2024 Oct;
29(5):e13144.
PMID: 39444157
Background: The eradication of Helicobacter pylori (H. pylori) is crucial due to its rising prevalence and increasing resistance. Bismuth-containing quadruple therapies (BcQTs) have been proposed as a viable treatment option;...
3.
Zeng S, Kong Q, Wu X, Duan M, Nan X, Yang X, et al.
Int J Antimicrob Agents
. 2024 Sep;
64(5):107325.
PMID: 39245326
Background: Empirical treatment needs to be supported by regional data, but knowledge of interregional differences is currently lacking in China. This study aimed to summarize and map the primary and...
4.
Ding Y, Zhang Q, Li R, Han Z, Zhao Q, Xu L, et al.
Helicobacter
. 2024 Aug;
29(4):e13121.
PMID: 39097924
Background: Current guidelines recommend bismuth-containing quadruple therapy for patients newly diagnosed with Helicobacter pylori (H. pylori) infection. We aimed to compare the efficacy and safety of tetracycline administered three times...
5.
Han Z, Zhang Q, Mirza I, Ding Y, Nan X, Zhao Q, et al.
Helicobacter
. 2024 Jun;
29(3):e13102.
PMID: 38873902
Background: The optimal dosage of tetracycline remains unclear for Helicobacter pylori eradication. Frequent dosing requirements may decrease patient adherence and increase the incidence of adverse events, potentially reducing treatment efficacy....
6.
Wu X, Duan M, Kong Q, Zeng S, Xu L, Li Y, et al.
Helicobacter
. 2024 May;
29(1):e13048.
PMID: 38716864
Current global variations exist in Helicobacter pylori (H. pylori) eradication regimens. Triple therapy (TT), bismuth quadruple therapy (BQT), and high-dose dual therapy (HDDT) currently represent the predominant regimens. These regimens...
7.
Ding Y, Duan M, Han Z, Song X, Zhang F, Wang Z, et al.
Dig Dis Sci
. 2024 May;
69(7):2540-2547.
PMID: 38700630
Background: Bismuth-containing quadruple therapy is the first-line treatment for eradicating Helicobacter pylori (H. pylori). The optimal duration for H. pylori eradication using bismuth-containing quadruple therapy remains controversial. Therefore, we aimed...
8.
Cao L, Dayimu A, Guan X, Duan M, Zeng S, Wang H, et al.
Inflamm Res
. 2024 Jan;
73(2):277-287.
PMID: 38184814
Aims: Inflammatory bowel disease (IBD) is a global disease. We aim to summarize the latest epidemiological patterns of IBD at the national, regional and global levels to give well-deserved attention...
9.
Zeng S, Wang J, Liu J, Lin M, Lin B, Ding Y, et al.
J Gastroenterol Hepatol
. 2023 Sep;
38(12):2097-2103.
PMID: 37702104
Background And Aim: After three treatment failures, Helicobacter pylori infection is deemed refractory as antibiotic treatment options become significantly limited. This study evaluated the efficacy and safety of a 14-day...
10.
Huang T, Duan M
Technol Health Care
. 2023 Jul;
32(2):565-572.
PMID: 37393443
Background: Hyperbilirubinemia is a common disorder in neonates, with premature infants at higher risk of developing the disorder. Objective: Glucose-6-phosphate dehydrogenase (G6PD) gene detection was used to determine the incidence...